Peter van Mourik

200 Chapter 9 65. Taylor-Cousar, J., Niknian, M., Gilmartin, G. & Pilewski, J. M. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States. J. Cyst. Fibros. 15 , 116–122 (2016). 66. Dekkers, J. F. et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci. Transl. Med. 8 , 344ra84 (2016). 67. Galapagos NV. Galapagos and AbbVie restructure CF collaboration. http:// hugin.info/133350/R/2222043/870053.pdf (2018). 68. Servidoni, M. F. et al. Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility. BMC Gastroenterol. 13 , 91 (2013). 69. Friedmacher, F. & Puri, P. Rectal suction biopsy for the diagnosis of Hirschsprung’s disease: a systematic review of diagnostic accuracy and complications. Pediatr. Surg. Int. 31 , 821–30 (2015). 70. Hinzpeter, A. et al. The importance of functional tests to assess the effect of a new CFTR variant when genotype-phenotype correlation is not possible. Clin. case reports 5 , 658–663 (2017). 71. European Medicines Agency: EMA/596489/2019: Kalydeco: EPAR - Medicine overview. https://www.ema.europa.eu/en/documents/overview/kalydeco-epar- medicine-overview_en.pdf. 72. European Medicines Agency: EMA/898508/2018 - Orkambi: EPAR - Medicine overview. https://www.ema.europa.eu/en/documents/overview/orkambi-epar- medicine-overview_en.pdf. 73. Emily’s Entourage. New Tool in the Toolbox: Emily’s Entourage Creates Nonsense Mutation Organoid. https://www.emilysentourage.org/new-tool-in- the-toolbox-emilys-entourage-creates-nonsense-mutation-organoid/. 74. Beekman, J. M. et al. Biobanking: towards increased access of biomaterials in cystic fibrosis. Report on the pre-conference meeting to the 13th ECFS Basic Science Conference, Pisa, 30 March-2 April, 2016. J. Cyst. Fibros. 16 , 616–621 (2017). 75. FDA. FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis. https://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm559212.htm (2017). 76. Wang, X., Koulov, A. V, Kellner, W. A., Riordan, J. R. & Balch, W. E. Chemical and biological folding contribute to temperature-sensitive DeltaF508 CFTR trafficking. Traffic 9 , 1878–93 (2008). 77. Pedemonte, N., Tomati, V., Sondo, E. & Galietta, L. J. V. Influence of cell background on pharmacological rescue of mutant CFTR. Am. J. Physiol. Cell Physiol. 298 , C866-74 (2010). 78. Rowe, S. M. et al. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm. Pharmacol. Ther. 23 , 268–78 (2010).